Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?

por Eyre, Toby A.
Publicado 2018

Correction: Predictive biomarkers for disease sensitivity in lymphoma – the holy grail for HDAC inhibitors?

por Eyre, Toby A.
Publicado 2019

The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives

por Eyre, Toby A., Riches, John C.
Publicado 2023

Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma

por Kesavan, Murali, Eyre, Toby A., Collins, Graham P.
Publicado 2019

Cellular Therapy in High-Risk Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter Syndrome

por Barbanti, Maria Chiara, Appleby, Niamh, Kesavan, Murali, Eyre, Toby Andrew
Publicado 2022

Efficacy of central nervous system prophylaxis with stand-alone intrathecal chemotherapy in diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy in...

por Eyre, Toby A., Djebbari, Faouzi, Kirkwood, Amy A., Collins, Graham P.
Publicado 2020

Development of a Conceptual Model of Chronic Lymphocytic Leukemia to Better Understand the Patient Experience

por Eek, Daniel, Blowfield, Matthew, Krogh, Calvin, Chung, Helena, Eyre, Toby A.
Publicado 2020

Acquired platelet dysfunction in newly diagnosed myeloma

por Mortimer, Joshua, Gray, Nicola, Desborough, Michael, Baker, Peter, Kothari, Jaimal, Eyre, Toby
Publicado 2021

Multiple myeloma in the very elderly patient: challenges and solutions

por Willan, John, Eyre, Toby A, Sharpley, Faye, Watson, Caroline, King, Andrew J, Ramasamy, Karthik
Publicado 2016

An Unusual Cause of Anaemia of Chronic Disease: Lisinopril-Induced Chronic Inflammatory State

por Eyre, Toby, Van-Hamel-Parsons, Victoria, Wang, Lai Mun, Hughes, Kathryn A., Littlewood, Timothy J.
Publicado 2011

P623: MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) OF PIRTOBRUTINIB VS VENETOCLAX CONTINUOUS MONOTHERAPY IN PATIENTS WITH RELAPSED/REFRACTORY CLL PREVIOUSLY TREATED WITH A COVALENT...

por Al-Sawaf, Othman, Jen, Min-Hua, Hess, Lisa, Zhang, Jiewen, Goebel, Benjamin, Pagel, John, Eyre, Toby
Publicado 2023

Single arm NCRI phase II study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s syndrome

por Eyre, Toby A, Clifford, Ruth, Roberts, Corran, Boyle, Lucy, Francis, Anne, Schuh, Anna, Dutton, Susan J
Publicado 2015

PB1930: EPIC: A NON-INTERVENTIONAL, OBSERVATIONAL STUDY OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS TREATED WITH FIRST-LINE ACALABRUTINIB THROUGH THE UK EARLY ACCESS PROGRAMME. INTERI...

por Eyre, Toby, Martinez-Calle, Nicolas, Walewska, Renata, Hickey, Joe, Blak, Betina, Pickin, Anna, Hunjan, Sukhjit, Condon, Orlaith, Hori, Satoshi
Publicado 2023

Treatment-free interval as an additional measure of efficacy in a large UK dataset of transplant ineligible myeloma patients

por Djebbari, Faouzi, Sharpley, Faye A., McLain-Smith, Susan, Vallance, Grant, Eyre, Toby A., Kothari, Jaimal, Moore, Sally, Ramasamy, Karthik
Publicado 2020

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly dia...

por Appleby, Niamh, Eyre, Toby A., Cabes, Maite, Jackson, Aimee, Boucher, Rebecca, Yates, Francesca, Fox, Sonia, Rawstron, Andrew, Hillmen, Peter, Schuh, Anna
Publicado 2019

Infection-related morbidity in a large study of transplant non-eligible newly diagnosed myeloma patients treated with UK standard of care

por Djebbari, Faouzi, Panitsas, Fotios, Eyre, Toby A., Prodger, Catherine, Davies, Fearn, Burton, Kieran, Khera, Akhil, Vallance, Grant, Moore, Sally, Kothari, Jaimal, Peniket, Andy, Ramasamy, Karthik
Publicado 2020

A retrospective observational study to evaluate the clinical outcomes and routine management of patients with chronic lymphocytic leukaemia treated with idelalisib and rituximab in...

por Eyre, Toby A., Preston, Gavin, Kagdi, Huseini, Islam, Amin, Nicholson, Toby, Smith, Harry W., Cursley, Adam P., Ramroth, Heribert, Xing, Guan, Gu, Lin, Rajakumaraswamy, Nishanthan, Fegan, Christopher
Publicado 2021

P1112: PATIENT-REPORTED OUTCOMES (PRO) AMONG PATIENTS WITH MANTLE CELL LYMPHOMA RECEIVING PIRTOBRUTINIB AFTER PRIOR COVALENT BTKI: INTERIM PRO ANALYSIS FROM THE BRUIN PHASE 1/2 STU...

por Cohen, Jonathon, Roeker, Lindsey, Cheah, Chan, Eyre, Toby, Patel, Krish, Woyach, Jennifer, Seymour, John, Wang, Michael, Wang, Yucai, Loubert, Angely, Payakachat, Nalin, Hess, Lisa, Abada, Paolo, Mato, Anthony R., Ghia, Paolo
Publicado 2023

Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib

por Bye, Alexander P., Kriek, Neline, Sage, Tanya, Rawlings, Suzannah J., Prodger, Catherine, Kesavan, Murali, Lees, Charlotte, Booth, Stephen, Cowen, Louise G, Shefferd, Kirsty, Desborough, Michael J., Gibbins, Jonathan M., Eyre, Toby A.
Publicado 2022

P618: LONG-TERM SAFETY WITH ≥12 MONTHS OF PIRTOBRUTINIB IN RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES

por Jurczak, Wojciech, Coombs, Catherine C., Shah, Nirav N., Woyach, Jennifer, Cheah, Chan Y., Patel, Krish, Maddocks, Kami, Wang, Yucai, E. Muehlenbein, Catherine, Wang, Chunxiao, Abhyankar, Sarang, Tsai, Donald E., Eyre, Toby A.
Publicado 2023